ストックスクリーナーアプリを入手
4.88
2.40%
-0.12
アフターアワーズ：
4.87
-0.010
-0.20%
前日終値:
$5.00
開ける：
$4.93
24時間の取引高:
57,006
Relative Volume:
0.25
時価総額：
$1.73B
収益：
$842.96M
当期純損益:
$-185.63M
株価収益率:
-14.29
EPS:
-0.3415
ネットキャッシュフロー:
$-228.52M
1週間 パフォーマンス:
+10.91%
1か月 パフォーマンス:
+2.52%
6か月 パフォーマンス:
+3.83%
1年 パフォーマンス:
-58.29%
1日の値動き範囲:
$4.845
$5.00
1週間の範囲:
$4.33
$5.10
52週間の値動き範囲:
$2.85
$12.00
Evotec Se Adr Stock (EVO) Company Profile
EVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
4.88 | 1.73B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
165.52 | 74.68B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.74 | 44.04B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.14 | 41.66B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.62 | 25.63B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.56 | 14.99B | 15.05B | -883.30M | 1.89B | -0.74 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-07 | ダウングレード | Jefferies | Buy → Hold |
| 2024-08-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-07-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-04-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-08 | アップグレード | Citigroup | Neutral → Buy |
| 2023-04-04 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-16 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-08-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2022-01-07 | 再開されました | Citigroup | Neutral |
すべてを表示
Evotec Se Adr (EVO) 最新ニュース
In-Vitro Toxicology Testing Market Projected to Reach USD 30.06 Bn by 2033 - GlobeNewswire Inc.
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer By Investing.com - Investing.com South Africa
Evotec SE withdraws acquisition offer - Investing.com India
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - Yahoo Finance
Evotec SE responds to media speculation - Investing.com India
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec SE responds to media speculation By Investing.com - Investing.com UK
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
After-hours movers: Applied Materials, Domino's Pizza, Evotec - Investing.com
Earnings call: Evotec SE maintains 2024 outlook amid strategic changes - Investing.com India
Evotec SE ADR earnings beat by $0.02, revenue fell short of estimates - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions - Yahoo Finance
Evotec stock outlook clouded by strategy update delays, warns Jefferies - Investing.com
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Stock Information - Evotec
Annual General Meeting - Evotec
Investor Relations - Evotec
Earnings call: Evotec SE reports revenue increase, plans cost cuts - Investing.com
Earnings call: Evotec SE revises 2024 outlook amid market challenges By Investing.com - Investing.com Canada
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' - Yahoo Finance
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
Antibody Discovery Market Size Expected to Surge to USD 4.8 - GlobeNewswire Inc.
Evotec stock holds Buy rating with price target from TD Cowen By Investing.com - Investing.com India
Healthcare Sector - Morningstar
Evotec's Underlying Demand Looks Stable as Momentum Builds, but Some Market Challenges Linger - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com Canada
QT to end this December with hardly a whimper: Barclays By Investing.com - Investing.com
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Evotec: R&D, Customer Growth Not Enough To Offset Headwinds - Seeking Alpha
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Evotec SEADR Shares Near 52-Week LowMarket Mover - Nasdaq
Evotec Se Adr (EVO) 財務データ
収益
当期純利益
現金流量
EPS
1.43%
0.64%
大文字化:
|
ボリューム (24 時間):